Welcome to our dedicated page for Synergy Chc SEC filings (Ticker: SNYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Synergy CHC Corp. (NASDAQ: SNYR) SEC filings page brings together the company’s official disclosures as a smaller reporting company in the consumer health and wellness sector. Synergy develops and markets branded products such as FOCUSfactor® brain-health supplements and functional beverages and Flat Tummy® women’s wellness offerings, and its regulatory filings provide detailed insight into how this business is structured and financed.
Through annual reports on Form 10‑K and quarterly reports on Form 10‑Q, Synergy reports product sales, license revenue, gross profit, operating expenses, operating income, net income, and non‑GAAP measures like EBITDA and Adjusted EBITDA. These filings also describe working capital, inventory levels, debt obligations, and stockholders’ equity or deficit, giving investors a view of how the company funds expansion of its FOCUSfactor® and Flat Tummy® brands.
Current reports on Form 8‑K document material events such as quarterly earnings releases, public offerings of common stock, changes to equity incentive plans, authorization of preferred stock, and board or executive changes. For example, Synergy has used Form 8‑K to report an underwritten public offering of common stock, amendments to its 2024 Equity Incentive Plan, authorization of preferred stock, and governance updates including director appointments and role transitions.
Registration statements such as the Form S‑1 provide additional background on the company’s business, risk factors, use of proceeds, capital structure, and status as a smaller reporting company. Investors interested in ownership changes and executive incentives can review equity plan amendments and related disclosures within these filings. On this page, AI-powered tools can help summarize lengthy documents, highlight key financial and governance changes, and make complex sections of 10‑K, 10‑Q, 8‑K, and S‑1 filings easier to understand.
Use this filings hub to track Synergy CHC Corp.’s official financial reporting, capital raises, governance actions, and other regulatory disclosures that shape the outlook for SNYR stock.
Synergy CHC Corp. (SNYR) filed an S-1 registration/prospectus describing a proposed public offering and continuing operations centered on two consumer health brands, FOCUSfactor and Flat Tummy. FOCUSfactor accounted for the majority of revenue (86% for the six months ended June 30, 2025; 88% for year ended December 31, 2024) and generated net revenues of $14.0 million for the six months ended June 30, 2025 and $30.7 million for the year ended December 31, 2024 (down from $37.2 million in 2023). For the six months ended June 30, 2025 the company reported net revenues of $16.3 million, net income of $2.3 million, EBITDA of $5.8 million and a working capital surplus of $12.4 million. The prospectus discloses an assumed public offering price of $3.92 per share, a 7% underwriting commission, and Underwriter Warrants exercisable at $4.31 (110% of the assumed price) with staged expirations over three to five years. The company details international expansion plans, manufacturing and distribution arrangements with major retailers, outstanding indebtedness arrangements and potential dilution metrics showing as-adjusted net tangible book value per share would remain negative under the assumed offering.
Synergy CHC Corp. (SNYR) delivered higher profitability in the second quarter of 2025 while executing material debt refinancing. Revenue for the three months ended June 30, 2025 totaled $8,134,996, including $1,400,000 of license revenue, producing gross profit of $6,238,605. Net income after tax was $1,473,237 for the quarter ($2,349,501 for the six months), driving basic and diluted EPS of $0.17 for the quarter and $0.27 for the six months. Total assets were $19,726,346 with cash and restricted cash of $1,558,561. Total liabilities were $32,105,546, and stockholders' deficit improved to $(12,379,200). In May 2025 the company drew a $17.5 million term loan (with a $2.5 million delayed draw) and used proceeds to repay and restructure prior indebtedness, record a $2,154,522 gain on settlement of notes payable, issue pre-funded warrants and shares in partial debt settlements, and record related debt discounts and issuance costs. Management reported a working capital surplus of $12,383,132 and concluded these actions alleviate substantial doubt about the company’s ability to continue as a going concern for the next twelve months.
Synergy CHC Corp. (SNYR) | Form 4 filed 07/31/2025
CEO/Chairman Jack Ross reported a series of open-market purchases between 06/11/25 and 07/30/25. In 24 separate transactions he bought 27,900 common shares at weighted-average prices ranging from $2.15-$3.90, spending roughly $80k-$90k and increasing his direct stake to 410,507 shares.
Including indirect holdings through four controlled entities—Rosscor Brands (300,000 sh), Gowan Private Equity (3,679,056 sh), Dunhill Distribution (269,635 sh) and Gowan Capital (136,559 sh)—Ross now beneficially owns ≈4.8 million shares.
No sales or derivative transactions were reported. The repeat buying by a 10% owner and key insider may signal confidence ahead of upcoming catalysts, but dollar amounts are modest relative to total market capitalization.
FAQ
What is the current stock price of Synergy Chc (SNYR)?
What is the market cap of Synergy Chc (SNYR)?
